X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (428) 428
humans (344) 344
index medicus (326) 326
pyrones - pharmacology (306) 306
male (297) 297
rats (219) 219
pyrones - administration & dosage (202) 202
pharmacology & pharmacy (186) 186
female (171) 171
mice (158) 158
pyrones - therapeutic use (148) 148
pyrones - chemistry (116) 116
hiv infections - drug therapy (93) 93
biochemistry & molecular biology (91) 91
dose-response relationship, drug (84) 84
rats, wistar (77) 77
pyrones - pharmacokinetics (73) 73
chemistry, medicinal (72) 72
pyridines - administration & dosage (72) 72
adult (71) 71
pyridines - therapeutic use (71) 71
administration, oral (65) 65
apoptosis (65) 65
drug therapy, combination (64) 64
pyrones - adverse effects (64) 64
pyrones - toxicity (63) 63
cell line, tumor (57) 57
rats, sprague-dawley (57) 57
middle aged (55) 55
hiv protease inhibitors - therapeutic use (53) 53
neurosciences (50) 50
oxidative stress (50) 50
pyridines - adverse effects (49) 49
analysis (48) 48
apoptosis - drug effects (48) 48
time factors (48) 48
oncology (47) 47
ritonavir (46) 46
toxicology (46) 46
research (45) 45
cancer (44) 44
phosphorylation (44) 44
pyrones (44) 44
hiv protease inhibitors - administration & dosage (43) 43
cells (42) 42
cell biology (40) 40
protease inhibitors (39) 39
treatment outcome (39) 39
cells, cultured (38) 38
hiv (38) 38
tipranavir (38) 38
activation (37) 37
health aspects (37) 37
in-vitro (37) 37
kojic acid (37) 37
drug interactions (36) 36
infectious diseases (36) 36
liver - drug effects (36) 36
molecular structure (36) 36
pyrones - blood (36) 36
ritonavir - administration & dosage (36) 36
disease models, animal (35) 35
enzyme inhibitors - pharmacology (35) 35
immunology (35) 35
research article (35) 35
anti-hiv agents - administration & dosage (34) 34
hypoglycemic agents - pharmacology (34) 34
inhibition (34) 34
rodents (34) 34
drug administration schedule (33) 33
microbiology (33) 33
plant sciences (33) 33
rabbits (33) 33
mice, inbred c57bl (32) 32
pharmacokinetics (32) 32
plant extracts - pharmacology (32) 32
cell line (31) 31
drug therapy (31) 31
hiv protease inhibitors - adverse effects (31) 31
medicine (31) 31
pyrones - metabolism (31) 31
vanadates - pharmacology (31) 31
article (30) 30
metabolism (30) 30
physiological aspects (30) 30
pyridines - pharmacology (30) 30
diabetes (29) 29
pyrones - isolation & purification (29) 29
signal transduction - drug effects (29) 29
structure-activity relationship (29) 29
therapy (29) 29
antineoplastic agents - pharmacology (28) 28
biotechnology & applied microbiology (28) 28
cell proliferation - drug effects (28) 28
hiv-1 - drug effects (28) 28
proteins (28) 28
ritonavir - therapeutic use (28) 28
toxicity (28) 28
care and treatment (27) 27
efficacy (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (728) 728
Japanese (16) 16
German (4) 4
Spanish (4) 4
Chinese (2) 2
Portuguese (2) 2
Russian (2) 2
Czech (1) 1
Dutch (1) 1
French (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 01/2016, Volume 11, Issue 1, p. e0144917
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naive HIV-1-infected patients because of its potency, unique resistance... 
PHENOTYPIC CHARACTERIZATION | ONCE-DAILY DOLUTEGRAVIR | MULTIDISCIPLINARY SCIENCES | TREATMENT-EXPERIENCED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | DISOPROXIL FUMARATE | DOUBLE-BLIND | DRUG-RESISTANCE | PROTEASE INHIBITOR TIPRANAVIR | PLUS RITONAVIR | HIV-INFECTED PATIENTS | Lamivudine - administration & dosage | Humans | Middle Aged | Drug Resistance, Viral | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Young Adult | Pyridines - adverse effects | Ritonavir - adverse effects | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Chemical and Drug Induced Liver Injury - etiology | Pyridines - therapeutic use | HIV Protease Inhibitors - adverse effects | Pyridines - administration & dosage | Tenofovir - adverse effects | Drug Administration Schedule | Ritonavir - administration & dosage | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | Proportional Hazards Models | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | HIV Protease Inhibitors - therapeutic use | Disease Progression | Pyrones - administration & dosage | HIV-1 - classification | Antiretroviral Therapy, Highly Active | Pyrones - adverse effects | Adolescent | Lopinavir - administration & dosage | Pyrones - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Aged | Gastrointestinal Diseases - chemically induced | Lopinavir - adverse effects | Slopes | Antiretroviral drugs | Therapy | Ritonavir | Lopinavir | Transaminase | Lamivudine | Drug resistance | Patients | CD4 antigen | Tenofovir | Highly active antiretroviral therapy | Randomization | Acquired immune deficiency syndrome--AIDS | Protease inhibitors | Antiretroviral agents | Human immunodeficiency virus--HIV | Quality | Adults | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Journal Article
Journal of Infection, ISSN 0163-4453, 2008, Volume 57, Issue 1, pp. 1 - 10
Summary Since 1996, the prognosis of those living with HIV and AIDS has improved significantly due to highly active antiretroviral therapy (HAART). Treatment... 
Infectious Disease | Tipranavir | Darunavir | Maraviroc | Etravirine | Salvage therapy | Raltegravir | INFECTIOUS DISEASES | maraviroc | UNITED-KINGDOM | EFFICACY | SAFETY | tipranavir | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | etravirine | DRUG-RESISTANCE | PROTEASE INHIBITORS | DOUBLE-BLIND | darunavir | INFECTION | PLACEBO-CONTROLLED TRIAL | salvage therapy | rattegravir | Triazoles - administration & dosage | Humans | Salvage Therapy | Cyclohexanes - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Cyclohexanes - therapeutic use | HIV Fusion Inhibitors - administration & dosage | Pyridazines - administration & dosage | Anti-HIV Agents - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Raltegravir Potassium | Pyridazines - therapeutic use | CCR5 Receptor Antagonists | Pyridines - therapeutic use | Triazoles - therapeutic use | Pyridines - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Pyrrolidinones - therapeutic use | Treatment Outcome | Clinical Trials as Topic | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Pyrones - administration & dosage | HIV Fusion Inhibitors - therapeutic use | Sulfonamides - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Pyrones - therapeutic use | HIV Infections - drug therapy | Sulfonamides - administration & dosage | Highly active antiretroviral therapy | Antiviral agents | Reverse transcriptase | Protease inhibitors | Proteases | HIV patients | HIV (Viruses) | Drug therapy | Drug resistance | HIV infection | Anti-HIV agents
Journal Article
Journal Article
Toxicology Letters, ISSN 0378-4274, 01/2017, Volume 265, pp. 9 - 16
Qing Ye Dan (QYD) is the whole plant of and used in Chinese folk medicine for the treatment of prostatitis, benign prostatic hyperplasia (BPH) and so on. This... 
Oxidative stress | Epithelial-mesenchymal transition | Benign prostatic hyperplasia | Swertiamarin | Qing Ye Dan | ACID | ALPHA | PROLIFERATION | KAPPA-B | MESENCHYMAL TRANSITION | INFLAMMATION | GROWTH | TOXICOLOGY | STROMAL CELLS | EXPRESSION | EXTRACT | Prostatic Hyperplasia - pathology | Rats, Wistar | Oxidative Stress - immunology | Epithelial-Mesenchymal Transition - drug effects | Male | Iridoid Glucosides - administration & dosage | Iridoid Glucosides - toxicity | Testosterone - pharmacology | Prostate - metabolism | Prostate - pathology | Prostate - immunology | Anti-Inflammatory Agents - therapeutic use | Prostate - drug effects | Anti-Inflammatory Agents - administration & dosage | Female | Anti-Inflammatory Agents - isolation & purification | Iridoid Glucosides - isolation & purification | Drugs, Chinese Herbal - administration & dosage | Drugs, Chinese Herbal - isolation & purification | Drugs, Chinese Herbal - therapeutic use | Anti-Inflammatory Agents - toxicity | Swertia - chemistry | Prostatic Hyperplasia - chemically induced | Pyrones - administration & dosage | Prostatic Hyperplasia - metabolism | Antioxidants - toxicity | Drugs, Chinese Herbal - toxicity | Antioxidants - therapeutic use | Testosterone - administration & dosage | Animals | Antioxidants - isolation & purification | Iridoid Glucosides - therapeutic use | Antioxidants - administration & dosage | Epithelial-Mesenchymal Transition - immunology | Pyrones - isolation & purification | Pyrones - therapeutic use | Prostatic Hyperplasia - prevention & control | Oxidative Stress - drug effects | Pyrones - toxicity | Toxicity Tests | Anti-inflammatory drugs | Testosterone | Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 466 - 475
Journal Article
Apoptosis, ISSN 1360-8185, 5/2017, Volume 22, Issue 5, pp. 597 - 607
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 10/2018, Volume 14, Issue 7, pp. 2143 - 2153